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a b s t r a c t
Since December 2015, the first dengue vaccine has been licensed in several Asian and Latin American
countries for protection against disease from all four dengue virus serotypes. While the vaccine demon-
strated an overall good safety and efficacy profile in clinical trials, some key research questions remain
which make risk-benefit-assessment for some populations difficult. As for any new vaccine, several ques-
tions, such as very rare adverse events following immunization, duration of vaccine-induced protection
and effectiveness when used in public health programs, will be addressed by post-licensure studies and
by data from national surveillance systems after the vaccine has been introduced. However, the complex-
ity of dengue epidemiology, pathogenesis and population immunity, as well as some characteristics of
the currently licensed vaccine, and potentially also future, live-attenuated dengue vaccines, poses a chal-
lenge for evaluation through existing monitoring systems, especially in low and middle-income coun-
tries. Most notable are the different efficacies of the currently licensed vaccine by dengue serostatus at
time of first vaccination and by dengue virus serotype, as well as the increased risk of dengue hospital-
ization among young vaccinated children observed three years after the start of vaccination in one of the
trials. Currently, it is unknown if the last phenomenon is restricted to younger ages or could affect also
seronegative individuals aged 9 years and older, who are included in the group for whom the vaccine has
been licensed. In this paper, we summarize scientific and methodological considerations for public health
surveillance and targeted post-licensure studies to address some key research questions related to live-
attenuated dengue vaccines. Countries intending to introduce a dengue vaccine should assess their
capacities to monitor and evaluate the vaccine’s effectiveness and safety and, where appropriate and pos-
sible, enhance their surveillance systems accordingly. Targeted studies are needed, especially to better
understand the effects of vaccinating seronegative individuals.
 2017 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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1. Introduction
With an estimated 96 million clinically apparent infections
every year, dengue is the most common mosquito-borne viral dis-
ease globally [1]. The highest disease burden is now found in Asia
and Latin America with expanding geographic distribution and co-
circulation of multiple dengue virus (DENV) serotypes [2]. Four
antigenically distinct serotypes (DENV1-4) are recognized and
infection with one is generally believed to confer life-long immu-
nity to that serotype (homotypic protection) while cross-
immunity to other serotypes (heterotypic protection) persists for
one or two years [3,4].
Most DENV-infections are asymptomatic or cause a mild illness,
but a small proportion of cases develop severe disease manifested
as plasma leakage, bleeding or severe organ involvement. For
example, in two large phase 3 trials of the now licensed dengue
vaccine carried out in 10 endemic countries, about 10,000 unvacci-
nated children aged 2–16 years served as controls. Among these
children there were 708 virologically-confirmed dengue infections
identified in the first 2 years of follow-up (2.9 and 4.6 episodes per
100 person-years in Latin America and Southeast Asia, respec-
tively), of which 30 (4%) were classified as dengue haemorrhagic
fever, including 2 (0.3%) with dengue shock syndrome [10]. Multi-
ple epidemiological studies have shown that the risk of developing
severe disease is higher after a heterotypic second DENV-infection
(estimated 0.5–2%) as compared to the risk following primary
infection [5–7]. Antibody-dependent enhancement of infection
has been proposed as a possible underlying mechanism [8,9]. The
determinants of severe disease include viral as well as human host
factors, such as age and ethnicity [8].
Starting inDecember2015, thefirst denguevaccine (Dengvaxia,
Sanofi-Pasteur) was granted market authorization in several coun-
tries in Asia and Latin America. This vaccine is a tetravalent, recom-
binant, live-attenuated vaccine with a yellow fever 17D vaccine
virus backbone, administered in a 3-dose schedule at 6-month inter-
vals. The vaccine has been licensed for individuals aged 9–45 years
living in dengue endemic areas, although both upper and lower
age limitmight vary by license. This vaccine is not intended as a rou-
tine vaccination for travellers [11]. Currently, the vaccine is mainly
available to the privatemarket, but it has been introduced in subna-
tional public sector programs in Brazil and the Philippines [12]. Two
other tetravalent live recombinant vaccines, TV003/TV005 and TDV,
are undergoing phase 3 trials (Table 1).
In July 2016, based on recommendations of the Scientific Advi-
sory Group of Experts (SAGE) on Immunization, the World Health
Organization (WHO) published a position paper providing guid-
ance for the use of Dengvaxia [13]. WHO recommends that coun-
tries should consider introduction of the vaccine only in
geographic settings (national or subnational) where epidemiologi-
cal data indicate persistent and high intensity of transmission.
Prior infection with DENV of any serotype, as measured by sero-
prevalence, should ideally be 70% or greater in the age-group tar-
geted for vaccination to maximize public health impact and cost-
effectiveness [14]. The main reason for this recommendation is
the differential performance of Dengvaxia by dengue serostatus
at the time of first vaccination, in terms of vaccine efficacy, and
possibly safety [13]. Details of the trial results informing the
WHO position are summarized below.
As for any new vaccine, some questions remain unanswered at
the time of licensure, which can only be studied once the vaccine is
widely used in the population. Accordingly, concerted post-
licensure evaluation of a new vaccine will be conducted by the
manufacturer according to a risk management plan (RMP), and
should also be planned by public health authorities that include
the vaccine in their national or subnational immunization pro-
gram. However, the complexity of dengue epidemiology, patho-
genesis and population immunity, as well as some characteristics
of the currently licensed dengue vaccine, pose considerable chal-
lenges as some research questions cannot be answered simply
through using routine surveillance systems and require either
enhanced (active) surveillance activities or targeted studies. Fore-
seeing the need for enhanced country surveillance and targeted
studies, considerations for post-licensure evaluation of live-
attenuated dengue vaccines have been previously published [15–
18]. In light of the results of the phase 3 clinical trials and the
WHO/SAGE recommendations, it is appropriate now to refine and
prioritize the needs for post-licensure data. Building upon these
previous considerations, the background paper of the SAGE work-
Table 1
Dengue vaccine candidates in clinical development (as of August 2017).*
Candidate vaccine name Manufacturer/
Developer
Vaccine type/platform Antigen Adjuvant Most advanced
trial phase
CYD-TDV (Dengvaxia) Sanofi Pasteur Live, recombinant
(based on a yellow fever
vaccine 17D backbone)
DENV-1–4 prM/E None Licensed
TV003 TV005 Butantan Institute Live, attenuated and recombinant
(DENV-2 in DENV-4 backbone)
DENV-1,3,4 whole genome,
DENV-2 prM/E
None Phase III
TDV (also referred to as TAK-003) Takeda Live, attenuated and recombinant
(DENV-1/3/4 in DENV-2 backbone)
DENV-2 whole genome,
DENV-1,3,4 prM/E
None Phase III
TDENV-PIV GSK/WRAIR/
Fiocruz
Inactivated DENV-1–4 whole genome AS03 Phase II
TDENV-LAV + TDENV-PIV WRAIR Live, attenuated and inactivated
(heterologous prime-boost)
DENV-1–4 whole genome Alum (with PIV) Phase I
V180 Merck Recombinant subunit (non-VLP) DENV-1–4 E protein ISCOMATRIX Phase I
TVDV NMRC DNA DENV-1–4 prM/E Vaxfectin Phase I
* Sources: World Health Organization (WHO) Global Observatory on Health R&D http://www.who.int/research-observatory/monitoring/processes/health_products/en/
and WHO vaccine pipeline tracker http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/.
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ing group on dengue vaccines [19], and discussions during a meet-
ing on ‘‘Targeting vaccination and post-licensure studies for the
licensed dengue vaccine” organized by WHO in June 2016 [20],
we summarize the current scientific background and highlight
important post-licensure studies that are feasible for early intro-
ducer countries to perform, as well as critical targeted studies that
can best be addressed in special research contexts. Second-
generation tetravalent live-attenuated dengue vaccines may have
different characteristics to the currently licensed vaccine, but the
surveillance activities and studies we propose are likely to be rel-
evant for the post-licensure evaluation of future live-attenuated
and, possibly, non-live dengue vaccines. We will not discuss the
studies that are needed to inform vaccine introduction decisions.
2. Key findings from phase 3 studies
Dengvaxia has been evaluated in two parallel phase 3 trials in
5 countries in Asia (trial CYD14) and 5 countries in Latin America
(trial CYD15) [21,22]. The trial in Asia included 10,275 participants
aged 2–14 years and the trial in Latin America 20,869 participants
aged 9–16 years. There was a random assignment, in a 2:1 ratio, to
the vaccine or the control group. Both trials included active surveil-
lance for dengue for 25 months after the first dose for the primary
efficacy endpoint (virologically-confirmed dengue disease) and
hospital-based surveillance for a further 4 years for additional
safety evaluation. In the hospital-based follow-up period, which
is ongoing, the incidence of hospitalization for dengue was
monitored to evaluate any potential predisposition in vaccinated
persons to more severe disease [23]. Serostatus at baseline was
assessed in a subset of trial participants (1983 and 1944
participants in CYD14 and CYD15, respectively). The proportion
of children having pre-vaccination antibodies against at least one
DENV-serotype increased with age [19] and, among participants
aged 9 years or older, was approximately 80% in both trials [21,22].
Based on pooled results from both trials, 3-dose vaccine efficacy
across all age-groups in the 25 months after the first dose was
60.3% (95% CI, 55.7–64.5) [23]. Efficacy varied by infecting serotype
(higher for DENV-3 and -4), age at time of first dose (65.6% and
44.6% in children aged 9–16 and <9 years, respectively), and was
higher for protection against more severe disease (80.8% against
dengue hospitalization and 93.2% against severe dengue in chil-
dren aged 9–16 years) [23]. Independent of age, vaccine efficacy
was higher among vaccinees who were dengue seropositive than
among those who were seronegative at baseline (70.1%; 95%CI
32.3–87.3 vs. 14.4%; 95%CI -111–63.5 in children aged <9 years,
and 81.9%; 95%CI 67.2–90.0 vs. 52.5%; 95%CI 5.9–76.1 in those aged
9–16 years) [23]. There are currently no data on the efficacy of the
vaccine against the primary endpoint beyond 25 months after the
first vaccine dose, as in this period surveillance was limited to hos-
pitalized cases only. Some data are expected to become available
as, later in the trials, active surveillance for the primary endpoint
was reinstated [23]. In children 9 years, the relative risk of hospi-
talized dengue, in the period 2 or more years after trial entry, was
lower in the vaccinated group, but moved closer to unity as time
progressed, suggesting waning protection within a few years
post-vaccination [19].
With respect to vaccine safety, the incidence of severe adverse
events following immunization (AEFI) was similar in the vaccine
and the control group [24]. Since Dengvaxia is a chimeric vaccine
using the yellow fever 17D strain virus as backbone, there was a
hypothetical risk of yellow fever vaccine-associated viscerotropic
or neurotropic disease [18]. No such adverse reactions were
observed during the trials, but the studies lacked sufficient power
to exclude risks below 0.1%.
In the 3rd year after the first dose, an interim safety analysis
demonstrated a relative risk (RR) of hospitalization for dengue of
0.50 (95% CI, 0.29–0.86), compared to the control group, among
those aged 9 years or older at first vaccination. However, in those
first vaccinated aged 2–5 years there was a significant excess of
dengue hospitalization in the vaccinated group (RR = 7.45; 95%CI
1.15–313.80). This was also the age-group with the lowest
pre-vaccination seroprevalence (51%) [21,23]. Among children
hospitalized for dengue <9 years of age, there were 12 cases of
severe dengue in the vaccine group and none in the control group;
no deaths occurred [23]. No difference was observed in the level of
viremia and cytokine profile of those vaccinated compared to
controls [23].
Since the pre-vaccination serostatus was assessed only in a sub-
set of participants, and the proportion of seronegatives in children
aged 9 years and older was small, stratified analysis of the risk for
dengue hospitalization or severe dengue by serostatus was not
informative. It remains unknown if the differential vaccine perfor-
mance is related to age, serostatus, or both factors. Several inter-
related biologic hypotheses have been discussed [19,23,25,26].
Since the efficacy of Dengvaxia is moderate, breakthrough infec-
tion, including severe disease, occur. One hypothesis for the excess
of dengue hospitalization in younger vaccinees is that, in seronega-
tives, Dengvaxia mimics a (first) silent primary monovalent or
bivalent infection and when heterologous cross-protection wanes,
the first wild-type infection acts like a second infection, leading to
more severe disease [8,27]. Younger childrenmay bemore suscepti-
ble to this phenomenon as this group includes a high proportion of
subjects who are dengue seronegative. Their immature immune
responses to the vaccine may induce antibodies with less affinity,
and their vascular physiology is more prone to plasma leakage
[19,23]. Since second infections after a natural primary infection
can also lead to enhanceddisease, the question remainswhy the risk
was significantly higher and not equal in the group of young vacci-
nees as compared to the control group. This could be explained by
the condensed enrolment period in the trial that clustered these
children to a first ‘‘dengue-like” (vaccine) exposure compared to
unvaccinated controls,whowould be primednaturally over a longer
period [19,23]. The risk for dengue hospitalization among vacci-
nated participants compared to controls in children first vaccinated
aged 2–5 years diminished in the 4th and 5th year of the trial and
was not statistically significant (RR = 1.42, 95%CI 0.58–3.99 and
RR = 1.50, 95%CI 0.27–15.15, respectively). Although, in the total
follow-up period from first vaccine dose an excess risk of hospital-
ized dengue in children first vaccinated aged 2–5 years was
observed, this was not statistically significant (RR = 1.26, 95%CI
0.76–2.13) [19].
An alternative explanation for the findings among young
children is that the observed breakthrough infections leading to
hospitalization were not analogous to secondary-like infection,
but just primary infection following a complete waning of homo-
or heterotypic protection or a primary vaccine failure. Since the
numbers were small, it cannot be excluded that the apparent
increase in risk of hospitalizations in the third year for age-group
2–5 years is just a chance, i.e. type II, statistical error. Nonetheless,
this increased risk of dengue hospitalization detected in children
<9 years in the third year in one of the clinical trials ultimately led
to the current vaccine indication for aminimum start age of 9 years.
3. Key research questions for the licensed vaccine
The manufacturer of Dengvaxia has developed a RMP, which
includes long-term monitoring of ongoing efficacy trials, post-
marketing pharmacovigilance and safety studies (e.g. background
rates of conditions that can mimic viscerotropism and neu-
rotropism, cohort event monitoring, pregnancy register), effective-
ness (e.g. community-based studies to evaluate impact on disease
transmission, facility-based studies to evaluate impact on hospital-
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ization and severe dengue, and monitoring of potential waning
immunity) and additional clinical studies (booster studies, adminis-
tration to clinical stable HIV+ subjects and co-administration with
human papilloma and tetanus-diphtheria-pertussis vaccines) [19].
While comprehensive, this RMP does not seem to address
directly the observed vaccine effect in seronegative individuals.
In addition, manufacturer-independent studies will be valuable,
particularly to assess the effectiveness and safety of the vaccine
in large public-funded programs. Key research questions related
to live-attenuated tetravalent dengue vaccines, along with activi-
ties planned by the manufacturer, are summarized in Box 1. Tar-
geted studies will be needed to answer some, while others could
be evaluated through establishing enhanced (active) surveillance
activities in selected health facilities or strengthening routine
monitoring systems in countries introducing the vaccine in their
public immunization program. These research questions aim to fill
gaps deemed important for country-level policy-making. Most of
the research questions can be grouped into one of the three main
areas (Box 1). First, what are the effects of vaccination when the
dengue vaccine is included in a public program? Second, what is
the vaccine effectiveness under field conditions? And third, does
vaccination of seronegative individuals increase the risk for hospi-
talized or severe dengue? If so, is the risk modified by waning
immunity or incomplete vaccination and what is the population-
level impact? Mathematical modelling based on the hypothesis
of secondary-type breakthrough infections suggests the vaccine
might increase the overall incidence of more severe dengue in set-
tings with low virus transmission (i.e. where the risk of two or
more DENV-infections is low) [14,18].
We propose key research questions that are relevant for an
extended risk-benefit-assessment. Out of the scope of this paper
are additional research questions related to dengue vaccines that
are relevant and warrant investments. For example, which biomar-
ker(s) can serve as immune correlates of protection or disease
enhancement, and do immunological effector mechanisms con-
tribute to clinical protection.
4. Methodological challenges when addressing implementation
and research questions
There are several methodological challenges to address these
key research questions. First, routine disease surveillance systems
mainly provide population-based data to compare disease inci-
dences before and after vaccine introduction to assess the impact
of a vaccination program. Based on mainly routine reporting sys-
tems, these data are limited by case ascertainment definitions,
diagnostic accuracy, heterogeneous outcome and severity criteria,
and variable surveillance and reporting intensity. Several studies
have shown substantial underreporting in routine surveillance sys-
tems [28,29], but as long as the level of underreporting is constant
this has little impact on trend analyses. Still, any impact of vaccina-
tion might not be detectable at population-level when only a small
fraction is vaccinated, when vaccination coverage is suboptimal or
if vaccine efficacy is only moderate. Also, natural year-to-year vari-
ations in dengue incidence and serotype distribution are substan-
tial and challenge the interpretation of temporal changes in
surveillance data.
Box 1 Outstanding research questions related to live-attenuated tetravalent dengue vaccines.
Safety-related questions
1. Is there a risk of enhanced disease associated with the currently licensed vaccine? And if there is a risk of vaccine-
associated enhanced disease:
1.1. What determines the risk (e.g. serostatus, age at time of vaccination, or other factors)?
1.2. Is the risk conferred by the vaccine similar to that conferred by natural infection?
1.3. How does it relate to the number of doses received?
1.4. Does waning of vaccine-induced immunity contribute to any risk and does any risk increase with time since vacci-
nation? Does a booster vaccination mitigate the risk?
1.5. Does immunity to other flaviviruses (induced either by natural infection or vaccination) modify any such risk?
2. What is the incidence of rare severe adverse events (esp. acute viscerotropic or neurotropic disease) and post-vaccination
dengue-like illness caused by vaccine viremia?
3. Is the vaccine safe in special risk groups, e.g. immunocompromised subjects and pregnant/lactating women?
Effectiveness and impact-related questions
4. What are the effects of vaccination when the vaccine is included in a public program? In particular:
4.1. What is the overall effect (direct and indirect protection) on the incidence of dengue and hospitalized/severe dengue
in the population?
4.2. Does vaccination reduce dengue transmission?
4.3. What is the program impact on the dengue serotype distribution in the area?
4.4. What is the effect on the epidemiology of other flaviviruses
5. What is the vaccine effectiveness under field conditions? In particular, are there differences in the vaccine effectiveness
5.1. against asymptomatic and symptomatic dengue?
5.2. by number of doses, age at vaccination (esp. adults) and serotype? This includes the question if fewer than three
doses are needed in any individuals (e.g. in those with pre-existing immunity)?
5.3. by time since vaccination (duration of protection)
5.4. by immune status in respect to other flaviviruses (e.g. yellow fever, Japanese encephalitis and Zika virus)?
Methodological questions
6. Can the serostatus at time of vaccination be retrospectively deduced with diagnostic tests, including in patients with post-
vaccination dengue virus infection?
7. In a country with limited resources, what are appropriate study designs to assess dengue vaccine effectiveness?
8. Can methods be devised to distinguish if, in a vaccinated patient with a severe breakthrough infection, the disease was
enhanced by the vaccine or developed independently from the vaccine?
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Second, for safety, spontaneous AEFI reporting systems are gen-
erally designed to ascertain events relatively close to the time of
vaccination and not to evaluate an increased risk of more severe
dengue if this occurs years after the vaccination, depending on
the intensity of exposure in the population and waning immunity
[30]. Every severe or hospitalized dengue infection in a vaccinated
Table 2
Post-licensure study designs and settings to address key research questions.
Research question Setting Options for study design Comment
Safety-related questions
Risk of severe dengue by serostatus
at vaccination, age-group 9 years
and older
Targeted study Prospective cohort study with serostatus
determined pre-vaccination or stored pre-
vaccination sera
Large sample size required; oversampling of sero-
naïve participants in high transmission settings.
Other questions can be addressed in such study,
e.g. effect of immunity to other flaviviruses
(Enhanced hospital-
based sentinel
surveillance)
Case-control study, if a valid test to
retrospectively identify serostatus at time of
vaccination is available. Compare severe cases
with non-severe cases
Currently no test is validated for this purpose
Risk of severe dengue by age at
vaccination, number of doses,
time since vaccination
Enhanced hospital-
based sentinel
surveillance
Case-control study. Compare proportion
vaccinated among severe cases vs. non-severe
cases, with stratifications by risk factors under
consideration
Cohort studies not suitable, since they would
require a very large sample size, off-label use, or
long study period. Limitation: Cannot adjust for
serostatus at time of vaccination
Risk of rare severe adverse events,
esp. acute viscerotropic /
neurotropic disease & post-
vaccination dengue-like illness
Routine national
adverse events
following
immunization (AEFI)
surveillance
Observed vs. expected analyses Expected background rates viscerotropism and
neurotropism and conditions that can mimic them
need to be established (part of the manufacturer’s
RMP)
Vaccine safety in special risk groups,
e.g. immunocompromised
subjects and pregnant/lactating
women
Routine national
adverse events
following
immunization (AEFI)
surveillance
Observed vs. expected analyses. Comparison of
outcomes in the risk group vs. non-risk group
Need to include the information of belonging to a
special risk groups as a variable for reporting. Risk
of bias in retrospective assessments/passive
surveillance
Targeted studies Randomized controlled trial for selected groups,
e.g. HIV + patients. (Register-based) cohort
studies, e.g. pregnancy exposure registry.
Comparisons of exposed vs. non-exposed
individuals belonging to the risk group; or
comparisons of outcome incidences in the risk
group vs. non-risk group or published reference
rates
Registries need to be established (part of the
manufacturer’s RMP)
Effectiveness and impact-related questions
Program impact on disease
incidence, impact on virus
transmission
Routine disease
surveillance system
(passive surveillance)
National passive disease surveillance, with
before-after analysis, using appropriate statistical
methods
Need for standardized surveillance protocol,
laboratory confirmation of at least a proportion of
cases, inclusion of all age-groups. Need to be
established before vaccine introduction. Analysis
must consider seasonality and annual fluctuations
in disease rates
Enhanced hospital-
based sentinel
surveillance
Enhanced surveillance with before-after analysis,
using appropriate statistical methods
Need to be established before vaccine introduction
Targeted study Studies assessing the risk of dengue in
unvaccinated persons in populations with high
vaccine coverage.
Household studies and studies of the prevalence
of infected mosquitoes in setting with varying
level of vaccine uptake, including before and after
vaccine introduction
Program impact on serotype
distribution
Laboratory-based
surveillance
Blood samples collected in outpatient clinics and
hospitals to be send to reference laboratory
Reference laboratory for serotyping and
genotyping to be identified or established
Vaccine effectiveness by age at
vaccination, serotype, number of
vaccine doses
Enhanced facility-
based sentinel
surveillance
Test-negative case-control design (TND) with
stratification by risk factors under consideration
Limitation: Cannot adjust for serostatus at time of
vaccination. TND not yet validated for the
assessment of dengue vaccine effectiveness, for
the time being this design should be conducted in
parallel to traditional case-control studies
Vaccine effectiveness by dengue
serostatus. Effect of immunity to
other flaviviruses on dengue
vaccine-induced protection
Targeted study Prospective cohort study with serostatus
determined pre-vaccination
Sample size will probably limit the analysis of
important co-variates (e.g. age at vaccination,
serotype)
Duration of vaccine-induced
protection
Enhanced hospital-
based sentinel
surveillance
Test-negative case-control design (TND) with
stratification of vaccine effectiveness estimates
by time since vaccination
Limitation: Cannot adjust for serostatus at time of
vaccination. TND not yet validated for the
assessment of dengue vaccine effectiveness, for
the time being this design should be conducted in
parallel to traditional case-control studies.
Targeted study Prospective cohort study to explore impact of
pre-vaccination serostatus on duration of
vaccine-induced protection
Long-term follow-up with active surveillance for
mild/severe dengue required. Sample size will
probably limit the analysis of important covariates
(e.g. age at vaccination, serotype, pre-vaccination
serostatus)
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person would, in theory, require reporting to the AEFI system and
trigger further investigations. However, there is currently no diag-
nostic tool that distinguishes enhanced disease potentially associ-
ated with the vaccine from that post-natural infection.
Third, in many countries there are no capacities to link informa-
tion routinely from existing databases (e.g. disease surveillance,
vaccination registries, and AEFI surveillance) because of the lack
of trained personal and systematic databases. Many immunization
information systems are still paper-based, and in many countries
patients also attend private clinics or hospitals that are not con-
nected to immunization and surveillance systems.
Fourth, there is no diagnostic test currently able to distinguish
the pre-vaccination serostatus of a dengue-vaccinated individual
retrospectively, and routinely assessing this before vaccination is
not currently considered feasible in large-scale routine vaccination
programs. However, when monitoring vaccine safety within the
public surveillance systems or targeted post-licensure studies,
knowledgeof serostatus at the timeof vaccinationwill be important.
This would help determining if an association between pre-
vaccination serostatus and post-vaccination enhanced risk of severe
disease exist, aswell asdetermining thedurationof vaccine-induced
protection in pre-vaccination seronegative vs. seropositive
individuals.
Fifth, prospective cohort studies with baseline testing for
dengue-specific and other flavivirus antibodies are needed. How-
ever, such studies would need to be large and include a sufficient
number of dengue-naïve participants, and participants would have
to be followed up for multiple years to assess duration of vaccine-
induced protection and any risk of enhanced disease that might not
be manifest for several years.
Finally, overall vaccine effectiveness may vary by population
and its ecology (transmission intensities, serotype distribution,
pre-existing immunity). Boosting effects from exposure to circulat-
ing wild-type DENV and other flaviviruses as well as other fla-
vivirus vaccines (e.g. Japanese encephalitis, yellow fever) may
affect the duration of vaccine-induced protection. Therefore, stud-
ies from multiple sites with different ecologies and population dis-
tributions will be needed.
5. Post-licensure surveillance of vaccine effectiveness and
safety
As for any other vaccine introduced in national or subnational
immunization programs, surveillance systems should be in place
and appropriate to assess if the dengue vaccine’s benefits are suf-
ficient to outweigh any risks in the population. Principles that
should also be applied for dengue vaccines but might require some
strengthening of recording systems include:
a. Documentation of administered vaccines: Vaccine coverage
monitoring at population-level is important not only to mea-
sure immunization program performance and accountabil-
ity, but to enable the interpretation of vaccine impact and
safety. To assess questions on duration of vaccine-induced
protection and effectiveness of incomplete vaccination
schedules and their potential effect on disease severity dur-
ing breakthrough infections, individual-level data on dates
and number of administered vaccine doses is crucial.
National or subnational electronic registries would facilitate
vaccination status ascertainment and individualized follow-
up as well as linkage to surveillance data.
b. Disease surveillance: Every country considering dengue vac-
cine introduction should consider collecting disease
surveillance data before and after vaccine introduction to
aid assessment of vaccination impact at population-level.
However, high-quality surveillance is needed for this pur-
pose. Surveillance must be based on internationally-
accepted case definitions with classifications into probable
and laboratory-confirmed cases, include ideally all age-
groups as well as case-based information on age, location,
times, laboratory confirmation and disease severity includ-
ing death. With the emergence of epidemics of other arbo-
viruses such as Zika and Chikungunya, the syndromic
approach that is being used in many countries for dengue
diagnosis has lost most of its validity. Despite the above-
described challenges in interpreting surveillance data, this
might constitute the only source to estimate vaccine
impact in countries that lack sufficient resources to imple-
ment enhanced sentinel-surveillance or targeted studies.
However, vaccine introduction may be an incentive to
strengthen surveillance systems to better define the local
dengue epidemiology as dengue becomes a vaccine pre-
ventable disease. Several studies have demonstrated that
enhancements in laboratory, sentinel-based surveillance,
and trained and motivated personnel contributed to
improvements in dengue case reporting [28].
c. AEFI surveillance: Spontaneous reporting of AEFI is important
to identify rare or unexpected adverse events potentially
associated with vaccination. Outcomes like viscerotropic or
neurotropic disease and hospitalizations for dengue-like ill-
ness should be reported and linked to immunization records.
The manufacturer’s RMP includes the assessment of back-
ground rates of conditions that can mimic viscerotropic or
neurotropic disease to evaluate changes in their rates fol-
lowing vaccine introduction [19]. Attempts should be made
to address the possible risk of vaccine-associated enhanced
disease in hospital-based sentinel-surveillance systems [18].
d. Virological surveillance: Routine monitoring of circulating
DENV sero- and genotypes is important to assess if there is
any effect on the serotype mixture [31]. Where possible,
DENV derived from post-vaccination cases should be
sequenced. In addition, the circulation of vaccine-derived
strains should, if possible, also be monitored, but seems unli-
kely to occur [32,33].
6. Targeted studies to assess vaccine effectiveness and safety
Post-licensure studies to address key research questions are
listed in Table 2. As highlighted in the table, the availability of
a diagnostic test that can retrospectively identify in a dengue-
vaccinated patient their pre-vaccination serostatus would greatly
facilitate addressing several research questions. It has been
suggested that the presence of anti-DENV envelope IgG in the
absence of dengue NS1 IgG antibodies in late convalescent
sera, characterizes a first DENV infection on a background of
Dengvaxia yellow fever vaccine–derived immunity in a dengue
seronegative person at baseline [25]. However, these tests
are not commercially available and not yet validated for this
purpose.
The test-negative design (TND) has been proposed for post-
licensure assessment of vaccine effectiveness. This case-control
design is an efficient and relatively inexpensive epidemiologic
method that can easily be embedded in a surveillance program
where patients are recruited prospectively through participating
ambulatory care clinics or hospitals [34]. The TND has been
extensively applied for the evaluation of several vaccines (e.g.
influenza and rotavirus) [34–36], and could also be used to mon-
itor dengue vaccine performance after introduction, by comparing
the vaccination status of persons presenting with febrile illness,
who are shown to either have or not have dengue. Other methods
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can be applied which utilize cases ascertained in active sentinel
surveillance systems. For example, traditional case-control, case-
coverage or case-cohort analyses. The TND offers advantage over
traditional case-control designs by reducing the possibility of
differential health-care-seeking behaviors among cases and non-
cases [34]. However, the TND’s validity has not been fully
explored in vector-borne infections like dengue. Such validation
is a priority.
There are a small number of study methodologies and set-
tings through which key research questions can be addressed
(Table 2).
(a) Studies that can be performed within the context of a public
health program
These include enhanced facility- or hospital-based surveillance
studies which should be considered by early introducer countries
to demonstrate the benefits and risks of dengue vaccination in
their population. These studies can be implemented in sentinel
hospitals with good diagnostic capacities (dengue PCR and NS1
antigen test) for at least 5 years following vaccine introduction.
The impact on dengue hospitalizations can be measured, vaccine
effectiveness against dengue hospitalization and duration of
protection can be assessed using the TND method, and long-term
safety can be evaluated through case-control studies. Such studies
might examine risk factors for severe disease, including vaccina-
tion timing and age.
(b) Studies that require special capacities and resources
Due to the limitations of existing surveillance systems and diag-
nostic tools, there is a need for targeted studies conducted in
selected settings. These include:
– Prospective cohort studies with assessment of the serostatus
prior to vaccination and, if possible, periodically thereafter, to
evaluate any relation between antibody levels and vaccine
effectiveness and safety and monitor for waning immunity or
boosting by asymptomatic DENV infections. Additional research
questions can be potentially addressed in such prospective
studies, such as the impact of immunity to other flaviviruses
(e.g. Japanese encephalitis or Zika virus) on effectiveness and
safety outcomes, the validity of future assays that can retro-
spectively distinguish the dengue serostatus at time of vaccina-
tion, or better correlates of protection and biomarkers for the
risk of severe disease as well as the role of T cell immunity.
– Studies that measure any impact on virus transmission would
also be valuable. For example, assessing whether the risk of
dengue is reduced in unvaccinated persons in populations with
high vaccine coverage.
– More advanced study designs, such as vaccine introduction
using a stepped-wedge design or cluster randomized controlled
trials, would provide an opportunity to measure indirect vac-
cine effects and overall effectiveness. However, such designs
are complex and require substantial resources.
7. Conclusion
As the first live-attenuated dengue vaccines are introduced in
larger populations, several unresolved research questions related
to their performance need to be answered. While some are com-
mon to all vaccines due to the limited number of participants in
pre-licensure clinical development programs, others arose from
phase 3 studies that unveiled the complexity of dengue as a pre-
ventable vector-borne infection. The current manufacturers’ RMP
contains a list of activities, including the extension of follow up
of participants in the phase 3 trials, which will help to address
some of these key research questions. However, as countries intro-
duce the vaccine, they are strongly encouraged to conduct their
own post-licensure monitoring and evaluation, which requires
planning and potentially strengthening vaccine surveillance and
immunization registry systems. Capacities for disease detection,
reporting and the assessment of long-term safety need reinforce-
ment, for example, though hospital-based sentinel surveillance.
Development and validation of suitable study methods, such as
TND, as well as diagnostic tools to retrospectively identify the
pre-vaccination serostatus are priorities. One important question
for vaccine introduction remaining to be answered and likely will
not be tackled by traditional or enhanced surveillance is the effects
of vaccinating seronegative individuals, both over time and with
respect to age. Targeted studies are needed on this. All entities that
collect data on vaccine effectiveness and safety are encouraged to
share with the scientific and public community information on
the methods and the results generated through these activities to
improve informed decision-making at the individual and popula-
tion level.
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